ALX Oncology (ALXO) Q3 2025: CD47-High Response Rate Hits 65%, Redefining Biomarker-Driven Oncology
ALX Oncology’s Q3 showcased a pivotal advance in biomarker-driven cancer therapy, as its Avorpacept program delivered a 65% response rate among CD47-high, HER2-positive gastric cancer patients—more than doubling control arm results and validating the predictive power of CD47 expression. The company’s dual-pronged strategy, focused on Avorpacept for HER2-positive breast and gastric cancers and the novel ALX2004 EGFR-ADC, now positions ALXO to target significant unmet needs with differentiated mechanisms and favorable safety. With cash runway into 2027 and data catalysts ahead, ALXO’s execution and clinical clarity stand out in a crowded immuno-oncology field.
Summary
- CD47 Biomarker Strategy: Avorpacept efficacy in CD47-high tumors signals a new era for precision immuno-oncology.
- Pipeline Progression: ALX2004 EGFR-ADC advances in the clinic, targeting broad, mutation-rich tumor types without legacy toxicity.
- Clinical Catalyst Visibility: Data milestones in 2026 will test ALXO’s ability to convert biomarker-driven promise into commercial opportunity.
Business Overview
ALX Oncology is a clinical-stage biotechnology company developing immuno-oncology therapies. Its lead asset, Avorpacept (EVO), is a fusion protein that blocks the CD47 “don’t eat me” signal, aiming to restore immune detection of cancer cells. ALXO’s pipeline also includes ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) for solid tumors. Revenue is not yet generated; value creation depends on clinical progress, biomarker-driven patient selection, and eventual out-licensing or commercialization of pipeline assets.
Performance Analysis
ALXO’s Q3 was defined by the release of mature data from the Aspen-06 trial, where Avorpacept combined with chemotherapy and trastuzumab delivered a 65% objective response rate (ORR) in CD47-high, HER2-positive gastric cancer patients, compared to 26% in control—demonstrating a more than twofold increase in efficacy. This benefit extended across key endpoints: median duration of response tripled to 25.5 months, median progression-free survival (PFS) more than doubled, and overall survival improved meaningfully, all with favorable hazard ratios. The consistency of benefit across multiple CD47 expression cutoffs underscores the robustness of the biomarker strategy.
ALX2004’s clinical entry marks a second pillar for ALXO, with rapid dose escalation and no dose-limiting toxicities reported in the first cohort. Preclinical data suggest efficacy across EGFR-positive tumor models, including those with KRAS, BRAF, and P53 mutations—historically challenging populations. Financially, a $67 million cash balance extends runway into Q1 2027, supporting the next wave of clinical readouts.
- Biomarker-Driven Outperformance: CD47-high selection delivered a 39 percentage point ORR delta versus control in gastric cancer.
- Safety Edge: Avorpacept’s inactive Fc region avoids the toxicity that derailed prior CD47-targeted agents, with a safety database exceeding 750 patients.
- Pipeline Breadth: ALX2004 is on track to provide initial safety data in 1H 2026, targeting EGFR-positive cancers with an improved therapeutic window.
ALXO’s execution—hitting enrollment and data milestones, maintaining capital discipline, and validating translational science—positions it as a leader in biomarker-guided immuno-oncology, though pivotal clinical and regulatory hurdles remain.
Executive Commentary
"The magnitude of benefit across many of these metrics was double or even triple those observed in the control arm, and also clearly compare very favorably with the large benchmark studies in second-line gastric cancer. Most importantly, these results support the potential to pursue a targeted oncology approach to additional tumor types with EVO."
Jason Letman, President & CEO
"The duration of response in all HER2 positive patients, irrespective of CD47 expression, was 15.7 months for the avorpacept plus TRP compared to 9.1 months for responders in the control arm. In the CD47 high group, the duration of response was three times longer for patients in the avorpacept trastuzumab RP arm compared to the control, with a median duration of response of 25.5 months versus 8.4 months."
Barb Quinkey, Chief Medical Officer
Strategic Positioning
1. Biomarker-Driven Patient Selection
ALXO’s clinical strategy centers on CD47-high expression as a predictive biomarker, enabling precision targeting of patients most likely to benefit from Avorpacept. This approach not only increases the probability of clinical success but also supports companion diagnostic development and market differentiation in both gastric and breast cancer indications.
2. Dual Mechanism and Combination Therapy
Avorpacept’s design leverages an inactive Fc region, minimizing off-target toxicity and enabling potent synergy with standard anti-cancer antibodies such as trastuzumab. This dual mechanism—blocking immune evasion and enhancing antibody-dependent phagocytosis—differentiates ALXO’s approach from failed first-generation CD47 therapies.
3. Expansion Into EGFR-Targeted ADCs
ALX2004’s entry into clinical development broadens ALXO’s opportunity set, targeting EGFR-expressing tumors with a differentiated ADC designed to overcome legacy toxicity and resistance issues. Early clinical progress and preclinical efficacy in mutation-rich models position ALX2004 as a potential first-in-class or best-in-class asset.
4. Capital Efficiency and Milestone-Driven Execution
ALXO’s cash runway into 2027 provides a clear window to reach key data milestones in both lead programs, supporting disciplined capital allocation and reducing near-term financing risk. The company’s focus on value-inflection points aligns its operational tempo with investor expectations for de-risking events.
5. Real-World Unmet Need and Market Opportunity
With an estimated 20,000 addressable patients annually in the U.S. and EU for HER2-positive, CD47-high breast cancer alone, ALXO’s targeted strategy addresses a multi-billion-dollar commercial opportunity where standard of care options post-ADC therapy are lacking.
Key Considerations
ALXO’s Q3 marked an inflection in clinical validation for its biomarker-driven approach, but the path to commercial impact will depend on execution, regulatory clarity, and competitive positioning as the oncology landscape evolves.
Key Considerations:
- Predictive Biomarker Validation: Robust efficacy in CD47-high populations de-risks the Avorpacept program and sets the stage for precision oncology expansion.
- Companion Diagnostic Development: Progress toward an IHC-based companion diagnostic is critical for regulatory approval and commercial adoption.
- EGFR-ADC Differentiation: ALX2004’s safety and efficacy profile will determine its ability to displace or complement existing EGFR-targeted therapies.
- Clinical Data Catalysts: Interim data from ongoing breast cancer and EGFR-ADC trials in 2026 will be pivotal for investor confidence and potential partnerships.
Risks
ALXO faces execution risk in translating strong biomarker-driven signals into larger, registrational trials, particularly as the evolving standard of care in HER2-positive cancers may complicate comparator selection and trial design. Regulatory hurdles for companion diagnostics, competitive pipeline activity from larger oncology players, and the inherent uncertainty of early-stage ADC safety and efficacy also pose material risks to the company’s long-term trajectory.
Forward Outlook
For Q4 2025 and into 2026, ALXO guided to:
- First patient dosed in the HER2-positive breast cancer trial in Q4 2025
- Interim data readout for Avorpacept breast study expected Q3 2026
- Initial safety data for ALX2004 EGFR-ADC in 1H 2026
For full-year 2026, management reiterated:
- Cash runway through Q1 2027, supporting all planned clinical milestones
Management emphasized continued disciplined execution, focus on biomarker-driven development, and anticipation of value-inflecting data readouts.
- HER2-positive breast and gastric programs remain top priorities
- ALX2004 dose escalation and expansion studies progressing on schedule
Takeaways
ALXO’s Q3 marks a turning point in biomarker-guided immuno-oncology, with Avorpacept’s efficacy in CD47-high tumors setting a new bar for targeted therapy development.
- Biomarker-Driven Outperformance: Avorpacept’s 65% ORR in CD47-high, HER2-positive gastric cancer patients validates the precision medicine thesis and supports expansion into breast cancer.
- Pipeline Breadth and Execution: ALX2004’s rapid clinical progress and differentiated design provide a second pillar of growth with broad applicability across EGFR-positive cancers.
- 2026 Data Catalysts: Upcoming interim and safety data will be critical in determining whether ALXO’s biomarker-driven approach can deliver durable value and commercial opportunity in a competitive oncology landscape.
Conclusion
ALX Oncology’s Q3 data reinforce its leadership in biomarker-driven immuno-oncology, with Avorpacept demonstrating transformative potential in CD47-high cancers and ALX2004 advancing rapidly in the clinic. The company’s disciplined execution and capital allocation set up a catalyst-rich 2026, but pivotal trial results and regulatory clarity will ultimately determine commercial success.
Industry Read-Through
ALXO’s results highlight the growing importance of predictive biomarkers and companion diagnostics in oncology drug development. The clear efficacy signal in CD47-high patients underscores the value of patient selection strategies, a trend likely to accelerate across immuno-oncology and ADC pipelines. ALX2004’s approach to EGFR targeting, with an improved safety profile and broad activity in mutation-rich tumors, signals a new direction for ADC innovation. Competitors in the CD47 and EGFR spaces will need to match both efficacy and safety, while the regulatory bar for biomarker-driven approvals continues to rise. The read-through is clear: precision medicine is no longer optional—it is a prerequisite for leadership in next-generation oncology.